Q1 FY27: revenue jumps 51% but consolidated PAT falls 29%

Revenue Growth 20pctEbitda Margin CompressionResults View source PDF Explain this filing

3BBLACKBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹1224.00

prior close

₹1181.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-4.1% vs market

Healthcare Service Provider peers, median of 26sector-2.0%-2.0% vs sector

On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.4

15m

-1.1

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0+0.1-4.1-2.0-2.0

Next day

-6.4+0.2-6.6-0.3-6.1

-6.0+0.6-6.6-0.3-5.8

-6.3-0.0-6.3-3.7-2.6

-5.2+0.5-5.7-2.3-3.0

-2.1+0.8-2.9-2.8+0.7

+2.9+0.6+2.4-0.4+3.4

15d

+20.6+1.3+19.3+0.4+20.2

+10.7-1.4+12.1-1.0+11.7

+18.7-0.6+19.3-5.8+24.5

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 results: standalone revenue up 13 percent to Rs 2,295 lakh, PAT up 13 percent to Rs 1,411 lakh. Consolidated revenue jumped 51 percent to Rs 3,349 lakh led by diagnostic kits (up 61 percent), but consolidated PAT fell 29 percent to Rs 898 lakh as employee and depreciation expenses surged from fuller subsidiary consolidation. Agrochem segment revenue declined 37 percent to Rs 143 lakh. Cost Auditor appointed for FY27. Limited review clean with no qualifications.

Likely market impact

Strong diagnostic segment growth, but consolidated margins compressed sharply due to higher subsidiary costs. Mixed picture for shareholders.